Dissection of TMEM165 function in Golgi glycosylation and its Mn2+ sensitivity

Elodie Lebredonchel, Marine Houdou, Sven Potelle, Geoffroy de Bettignies, Céline Schulz, Marie-Ange Krzewinski Recchi, Vladimir Lupashin, Dominique Legrand, André Klein, François Foulquier

To cite this version:


HAL Id: hal-02390802
https://hal.archives-ouvertes.fr/hal-02390802
Submitted on 26 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Dissection of TMEM165 function in Golgi glycosylation and its Mn$^{2+}$ sensitivity

Elodie Lebredonchel$^{1,2}$, Marine Houdou$^1$, Sven Potelle$^3$, Geoffroy de Bettignies$^1$, Céline Schulz$^1$, Marie-Ange Krzewinski Recchi$^1$, Vladimir Lupashin$^4$, Dominique Legrand$^1$, André Klein$^{1,2}$ and François Foulquier$^{1*}$

$^1$ Univ. Lille, CNRS, UMR 8576 – UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F- 59000 Lille, France.
$^2$Centre de Biologie et Pathologie, UAM de glycopathologies, Lille Medical Center, University of Lille, 59000 Lille.
$^3$Institut de Duve, 1200 Bruxelles, Belgium
$^4$Department of Physiology and Biophysics, College of Medicine, University of Arkansas for Medical Sciences, Biomed 261-2, Slot 505, 200 South Cedar St., Little Rock, AR 72205, USA.

*Address correspondence should be sent to: François Foulquier (francois.foulquier@univ-lille.fr)

Adresse : Univ. Lille, CNRS, UMR 8576 – UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France
Tel. +33 3 20 43 44 30
Fax. +33 3 20 43 65 55
HIGHLIGHTS

- TMEM165 is involved in Golgi glycosylation
- TMEM165 is highly sensitive to Mn$^{2+}$ concentration
- The UPF0016 amino acids are crucial for TMEM165 in Golgi glycosylation and Mn$^{2+}$ sensitivity

ABSTRACT

Since 2012, the interest for TMEM165 increased due to its implication in a rare genetic human disease named TMEM165-CDG (Congenital Disorders of Glycosylation). TMEM165 is a Golgi localized protein, highly conserved through evolution and belonging to the Uncharacterized Protein Family 0016 (UPF0016). Although the precise function of TMEM165 in glycosylation is still controversial, our results highly suggest that TMEM165 would act as a Golgi Ca$^{2+}$/ Mn$^{2+}$ transporter regulating both Ca$^{2+}$ and Mn$^{2+}$ Golgi homeostasis, the latter being required as a major cofactor of many Golgi glycosylation enzymes. Strikingly, we recently demonstrated that besides its role in regulating Golgi Mn$^{2+}$ homeostasis and consequently Golgi glycosylation, TMEM165 was sensitive to high manganese exposure. Members of the UPF0016 family contain two particularly highly conserved consensus motifs E-φ-G-D-[KR]-[TS] predicted to be involved in the ions’ transport function of UPF0016 members. In this paper we wanted to investigate the contribution of these two specific motifs in the function of TMEM165 in Golgi glycosylation and in its Mn$^{2+}$ sensitivity.

Our results showed the crucial importance of these two conserved motifs and underline the contribution of some specific amino acids in both Golgi glycosylation and Mn$^{2+}$ sensitivity.

KEYWORD: TMEM165, CDG, UPF0016, Golgi glycosylation, Mn$^{2+}$
ABBREVIATIONS
Chloroquine: CQ
Congenital Disorders of Glycosylation: CDG
Golgi Phosphoprotein 4: GPP130
Endoplasmic Reticulum: ER
Lysosomal-associated membrane protein 2: LAMP2
Manganese: Mn
Manganese, ion (2+): Mn^{2+}
Manganese (II) chloride tetrahydrate: MnCl_2
Transmembrane Protein 165: TMEM165
Secretory-Pathway Ca^{2+}-ATPase 1: SPCA1
Photosynthesis Affected Mutant 71: PAM71
Uncharacterized Protein Family: UPF
1. INTRODUCTION

Congenital Disorders of Glycosylation (CDG) are a rapidly expanding family of rare inborn errors of metabolism. The first cases were reported 38 years ago, today more than hundred different CDG types have been identified and characterized [1]. The frequency is comprised between 1/50 000 and 1/100 000 births, but is probably underestimated. While few X-linked defects have been described, the transmission is autosomal recessive in most cases [1]. CDG are classified in two groups, in CDG-I, steps that occur during Lipid Linked Oligosaccharides (LLO) synthesis in the Endoplasmic Reticulum (ER) are affected, whereas in CDG-II, the defect takes place after the oligosaccharide transfer onto proteins [2]. Clinical phenotypes of CDG patients are multisystemic with a broad spectrum whose severity is unpredictable but often associated with neurological defects.

In 2012, a new CDG subtype called TMEM165-CDG or CDG-IIk (OMIM #614727) has been described [3]. To date, a dozen of TMEM165-CDG patients have been diagnosed with a common semiology worldwide. The most severe phenotypes present a growth retardation resistant to human growth hormone leading to dwarfism, associated with a psychomotor retardation, microcephaly, facial hypoplasia, hypotonia, seizure, hepatosplenomegaly with an increased level of liver transaminases, and creatine kinase [4]. Some patients also harbor cardiac defects [5] but the pathognomonic signs remain bone and cartilage dysplasia with early osteoporosis assessable by tomodensitometry. All TMEM165-CDG patients present Golgi glycosylation defects characterized by a strong hypogalactosylation of total serum N-glycoproteins [3].

This CDG is due to a defect in TMEM165 protein, also named TPARL [3], a 324 amino-acids transmembrane protein member of the UPF family 0016 (Uncharacterized Protein Family 0016; Pfam PF01169). This protein is mainly localized in Golgi membranes [3,6], predominantly in trans-Golgi subcompartment. Similarly to other UPF0016 family members,
TMEM165 is highly conserved throughout evolution (919 different species in the prokaryotes and 405 species in eukaryotes) [7].

The cellular and molecular functions of UPF0016 family members are not completely deciphered and remain controversial. Gdt1p (Grc1 dependent translation factor 1), the yeast ortholog of TMEM165 in *Saccharomyces cerevisiae* was initially postulated to be an exchanger Ca\(^{2+}\) / H\(^{+}\) [8]. Recent results however interrogate about the nature of the exchanged ions. Unexpectedly, PAM71 (Photosynthesis Affected Mutant 71), the *Arabidopsis thaliana* plant ortholog of TMEM165 has been shown to function as a Ca\(^{2+}\) / Mn\(^{2+}\) cation antiport transporter localized in the thylakoid membranes system and then crucial for the regulation of chloroplastic Mn\(^{2+}\) homeostasis [9]. In addition, we recently demonstrated that the Golgi glycosylation defect due to TMEM165 deficiency also resulted from a defect in Golgi Mn\(^{2+}\) homeostasis [10]. Very importantly, a slight Mn\(^{2+}\) supplementation is sufficient to suppress the observed Golgi glycosylation defect in both deficient yeasts and human cells [11]. Furthermore, our recent studies suggested the function of Gdt1p as a Ca\(^{2+}\) / Mn\(^{2+}\) cation transporter [12]. In agreement with these results, Thines and collaborators have recently demonstrated that the yeast protein Gdt1p transports Mn\(^{2+}\) ions and thereby regulates manganese homeostasis in the Golgi [13].

Protein sequence alignments between PAM71, TMEM165 and Gdt1p underline highly conserved amino acids (Fig. 1) [12]. Two patterns of highly conserved successive amino acid sequences emerge from this alignment: E-x-G-D-K-[TF] and E-x-G-D-R-[SQ]. These motifs are enshrined in the first and fourth transmembrane protein domains (TM1 and TM4) (Fig. 1). In this paper we particularly explored the contribution of these two highly conserved motifs in the function of TMEM165 in Golgi glycosylation and also in its Mn\(^{2+}\) sensitivity.
2. MATERIAL and METHODS

2.1 Sequence alignment
Uniprot accession codes are: Homo sapiens TMEM165_HUMAN, Arabidopsis thaliana PAM71_ARATH and Saccharomyces cerevisiae GDT1_YEAST.

2.2 Cell culture, transfection and treatment.
Control and KO TMEM165 HEK293T cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Lonza, Basel, Switzerland), at 37°C in humidity-saturated 5% CO₂ atmosphere. Transfections were performed using 4µl of Lipofectamine 2000® (Thermo Scientific) for 0.5µg of plasmid for each well of 6 wells-plate at 70% confluence in 1ml DMEM medium. Transfections were stop after 5 hours. Wells were split 24 hours after transfection and treated 48 hours post-transfection. Manganese (II) chloride tetrahydrate, from Riedel-de-Haën (Seelze, Germany) treatment 500µM was pursued for 4 and 8 hours. Chloroquine (ICN Biomedicals) 100µM was added one hour before manganese as a pretreatment.

2.3 Constructs, vector engineering and mutagenesis
Mutated TMEM165 plasmids were generated and supplied by e-Zyvec (Lille, France).

2.4 Antibodies and other reagents
Anti-TMEM165 and anti–β-actin antibodies were purchased from MilliporeSigma (Burlington, MA, USA), anti-LAMP2 antibody from Santa Cruz Biotechnology (Dallas, TX, USA) and anti-GM130 antibody from BD Biosciences. Polyclonal goat anti-rabbit IgG and goat anti-mouse IgG Horse Radish Peroxidase-conjugated were from Dako (Denmark).
2.5 Immunofluorescence staining

Cells were seeded on coverslips for 12 to 24h, washed once in Dulbecco's Phosphate Buffer Saline (DPBS, Lonza) containing Calcium and Manganese and fixed with 4% paraformaldehyde (PAF) in PBS (Phosphate Buffer Saline) pH 7.3, for 30 min at room temperature. Coverslips were subsequently washed three times with PBS. Cells were permeabilized with 0.5% Triton X-100 in PBS for 15 min then washed three times with PBS. Coverslips were then saturated for 1h in blocking buffer [0.2% gelatin, 2% Bovine Serum Albumin (BSA), 2% FBS (Lonza) in PBS], followed by the incubation for 1h with primary antibody diluted at 1:100 in blocking buffer, except for GPP130 that was diluted at 1:300. After washing with PBS, cells were incubated for 1h with Alexa 488- or Alexa 568- secondary antibody (Life Technologies) diluted at 1:600 in blocking buffer. After three washes with PBS, coverslips were mounted on glass slides with Mowiol. Fluorescence was detected through an inverted Zeiss LSM700 confocal microscope. Acquisitions were done with ZEN pro 2.1 software (Zeiss, Oberkochen, Germany).

2.6 Image Analyses

Immunofluorescent images were edited using imageJ software (http://imagej.nih.gov/ij) developed by Fiji©.

2.7 Western Blotting

Cells were collected in PBS after 2 washes and centrifuged at 6000 rpm for 10 min. Cells were lysed in RIPA buffer [Tris/HCl 50mM pH 7.9, NaCl 120mM, NP40 0.5%, EDTA 1mM, Na3VO4 1mM, NaF 5mM] supplemented with a protease inhibitors mix (Roche Diagnostics, Penzberg, Germany) by a 30 min centrifugation at 14 000 rpm. Concentration of extracted
proteins was determined with the Micro BCA™ Protein Assay Reagent kit (Thermo Fisher Scientific, Waltham, MA USA). For LAMP2 study only samples were preheated 10 min at 95°C. 10 or 20 µg of total proteins of each sample were dissolved in reducing NuPage® Sample buffer and resolved by MOPS 4-12% Bis-Tris gel (Thermo Fisher Scientific, Waltham, MA USA) and then transferred with iBlot 2 Dry Blotting System (Thermo Fisher Scientific, Waltham, MA USA). Nitrocellulose membranes were blocked 1h in TBS (Tris Buffer Saline) containing 0.05 % Tween 20 5% (w/v) non-fat dried milk for at least 1h at room temperature, then incubated 1h with primary antibodies (used at a dilution of 1:2000 for TMEM165, 1: 20,000 for β Actin) and overnight for LAMP2 primary antibody 1:20 000. After three 5min-TBS-T washes, membranes were incubated with respective secondary antibodies for 1h (1:10 000 dilution for polyclonal goat anti-rabbit IgG and 1:20 000 for goat anti-mouse IgG Horse Radish Peroxidase-conjugated).
Signal was detected using chemiluminescence reagent (Pierce™ Pico Plus Western Blotting Substrate (Thermo Fisher Scientific, Waltham, MA USA) on imaging film (GE Healthcare, Buckinghamshire, UK) or Camera Fusion® (Vilber Lourmat) and its software.
3. RESULTS

3.1 Functionality of TMEM165 mutants in Golgi glycosylation

The ability for TMEM165 to rescue LAMP2 glycosylation defect in TMEM165 KO HEK293T cells was used to investigate the involvement of each amino acids of the two highly conserved sequences. To explore this, 10 different mutations in the most conserved amino acids that lay in the two signature-motifs were generated (Fig. 1). The wild type (wt-) and mutated forms of TMEM165 were then transiently expressed in TMEM165 KO HEK293T cells and the Golgi glycosylation of LAMP2 was followed by western blot experiments as previously described [14] (Fig. 2A). Compared to untransfected cells (KO), the expression of the wt-TMEM165 rescued glycosylated forms of LAMP2 similar to what can be seen in control cells. Even though the mutated forms of TMEM165 transfection gave heterogeneous results (Fig. 2A), only 3 mutants showed a partial restoration of LAMP2 glycosylation: E108G-, K112G- and R252G-TMEM165, E108G- and R252G- giving the mildest restorations. Interestingly among all our mutants, 7 of the conserved E-x-GDKT/ E-x-GDRSQ motifs are unable to restore LAMP2 glycosylation (Fig. 2B). The mutants (D111G-, T113G-, F114G-, E248G-, D251G-, S253G-, Q254G) were found unable to restore LAMP2 glycosylation (Fig. 2B). This result is characteristic from these two motifs as most of the investigated TMEM165 mutated forms, except G304R (patient mutation), were able to rescue LAMP2 glycosylation (Supp. Fig. 1).

To assess these results, the expression of the mutated forms of TMEM165 was then investigated by western blot experiments. Although the TMEM165 profile was found heterogeneous with two major bands, there was no major difference in TMEM165 expression level for the mutated forms (Fig. 2A). Altogether these results emphasize the importance of specific amino acids of the two conserved motifs in TMEM165 function in Golgi glycosylation.
3.2 Subcellular localization of TMEM165 mutants

The functionality of TMEM165 mutants in Golgi glycosylation depends on the TMEM165 mutants’ expression but also on their subcellular Golgi localization. To reinforce the above results, the Golgi localization of the mutated forms of TMEM165 was investigated by immunofluorescence and confocal microscopy experiments. Most of the mutated forms of TMEM165 displayed Golgi localization as observed by colocalization experiments using the GM130 Golgi marker (Fig. 2C, 2D). Very interestingly, the D251G- and S253G-TMEM165 mutants, did not entirely colocalize with GM130 as vesicular structures localized throughout the cytoplasm could be detected. To further tackle the subcellular localization of these mutants, immunofluorescence staining using the lysosomal/ endosomal intracellular marker LAMP2 was performed. A partial colocalization for these mutated forms was observed with LAMP2, demonstrating the differential subcellular localization (Supplementary Figure 2A and B). For these mutants, it is likely that the observed lack of LAMP2 glycosylation restoration results from a TMEM165 subcellular mislocalization.

3.3 Sensitivity of TMEM165 mutants to manganese exposure

We recently highlighted that, when exposed to high manganese concentration, TMEM165 was efficiently targeted to lysosomes for degradation [15]. As for the glycosylation study, we wanted to investigate the Mn⁺ sensitivity of these different mutants. To evaluate this point, wild-type and mutated forms of TMEM165 were transiently transfected in KO cells. The impact of high Mn⁺ concentration supplementation on the stability and subcellular localization was then investigated during a 4 and 8h time course by western blot (Fig. 3) and immunofluorescence experiments (data not shown). Diagrams under each mutant’s western blot describe the quantification of the remaining TMEM165 after 4 and 8h of Mn⁺ treatment.
As previously published [15], we observe that TMEM165 in normal HEK293T cells is highly sensitive to manganese, with a complete loss of this protein after 8h treatment (Fig. 3A). Same result is obtained after transfection of the wild-type form of TMEM165 in HEK293T KO TMEM165 cells with a loss over 75% of TMEM165 expression after 4 hours manganese treatment (Fig. 3A).

Concerning the mutated forms of TMEM165, 5 are found partially resistant, E108G, D111G, T113G, D251G and S253G. At the opposite, K112G, F114G, E248G, R252G and Q254G are sensitive to manganese treatment. These results were confirmed by immunofluorescence confocal microscopy (data not shown) and demonstrate the crucial importance of specific amino acids in the differential Mn induced sensitivity of TMEM165.

3.4 The functional mutants are targeted and degraded into lysosomes

We recently established that the Mn²⁺ induced degradation of TMEM165 was inhibited by chloroquine treatment [15]. To assess whether the mutated forms of TMEM165 fall under the same regulation, the stability of wt- and mutated forms of TMEM165 were analyzed by western blot and immunofluorescence after Mn²⁺ exposure, in the presence or the absence of chloroquine. The degradation of every mutated forms of TMEM165 was completely blocked by chloroquine (data not shown). The molecular mechanism by which TMEM165 is sent to lysosomes following Mn²⁺ exposure is currently unknown. Monoubiquitination is known to be a very efficient mechanism to target proteins for lysosomal degradation. It appears that the cytosolic loop of TMEM165 contains 4 lysine residues K198, K199, K200 and K208 that could be involved in the Mn²⁺ induced lysosomal targeting. In order to investigate the role of these lysines, TMEM165 mutants (K198R, K199R, K200R, K208R and K198-K200R) were generated and analyzed by western blot and immunofluorescence after Mn²⁺ exposure, in the
presence or in the absence of chloroquine (Supp. Figure 3). We observed that after Mn-exposure, the lysine mutants of TMEM165 were localized in the Golgi and were degraded similarly to what is observed for wt-TMEM165. Altogether, these results indicate that the lysine residues of the cytosolic loop are not involved in the expression, neither in the Golgi localization nor in its Mn--induced degradation of TMEM165.
4. DISCUSSION

Although the precise molecular and cellular functions of TMEM165 are still under debate, the functional role in Golgi glycosylation is now clearly established. The link between TMEM165 and cellular/Golgi Mn\(^{2+}\) homeostasis maintenance is strongly hypothesized by (i) the alteration of GPP130 Mn\(^{2+}\) induced degradation in TMEM165 depleted cells, (ii) the restoration of Golgi glycosylation by Mn\(^{2+}\)-supplementation [11], (iii) the TMEM165 Mn\(^{2+}\) sensitivity [15]. It is now highly suspected that TMEM165 functions as a Golgi Ca\(^{2+}/\) Mn\(^{2+}\) transporter regulating both Ca\(^{2+}/\) Mn\(^{2+}\)-Golgi homeostasis. As observed in yeasts, the Golgi glycosylation defect due to a lack of TMEM165 would result in an alteration of the Golgi Mn\(^{2+}\)-homeostasis crucial for the activities of Golgi glycosyltransferases using UDP-sugars as donors [11]. TMEM165 is a member of the UPF0016 family that has the particularity to contain two highly conserved consensus motifs E-φ-G-D-[KR]-[TS]. Our previous results showed that the E-φ-G-D-K-T motif (motif 1) was facing the cytosol while the E-φ-G-D-R-S (motif 2) was exposed to the Golgi luminal side and hence are predicted to be involved in the transport function of UPF0016 members [15]. In this paper we wanted to further understand the contribution of these two highly conserved motifs in the role of TMEM165 in Golgi glycosylation and also in its sensitivity to high Mn\(^{2+}\) concentration.

Our results first emphasized that some of the mutated forms of TMEM165 are unfunctional in their capacities to rescue Golgi glycosylation. The mutation of the amino acid E108G, first described in CDG-IIk patients, does not seem to strongly affect the function of TMEM165 in Golgi glycosylation as a slight restoration of LAMP2 glycosylation is observed. This interrogates on the molecular basis of the disease linked to this mutation. At the opposite, the E248G mutation (second motif) is found unfunctional in rescuing Golgi glycosylation. Interestingly, the polar amino acids (T113 and S253) are also found crucial for the function of TMEM165 in Golgi glycosylation while basic amino acids (K112 and R252) are completely
dispensable. We could hypothesize that these polar amino acids, via post-translational modifications, play a crucial role in the regulation of TMEM165 functionality. As proposed for yeasts, it is most likely that amino acids of the two conserved motifs constitute the cation binding sites of TMEM165. In such hypothesis, mutations in specific amino acids of the two conserved motifs alter the transport function of TMEM165 by impairing cation affinity or pocket conformation changes.

The other particularity of TMEM165 is its sensitivity to high Mn\(^{2+}\) concentration. We recently demonstrated that following high Mn\(^{2+}\) exposure, TMEM165 was targeted to lysosomes for its degradation [15]. The targeting molecular mechanism is unclear but recent investigations propose the requirement of Sortilin in the Mn\(^{2+}\) induced degradation of TMEM165 [16]. The Mn\(^{2+}\) sensitivity of the mutated forms of TMEM165 was evaluated. As pointed for the glycosylation most of the generated mutated forms of TMEM165 are resistant to Mn\(^{2+}\) exposure and only few are sensitive. Our results demonstrate that the acidic amino acids (E and D) of the first conserved motif are crucial in conferring the Mn\(^{2+}\) sensitivity to TMEM165. The two resistant mutants D251G and S253G of the second motif are less sensitive to manganese presumably due to their Golgi mislocalization. Another interesting observation deals with the T113G that is also clearly found resistant to Mn exposure while correctly Golgi localized. The roles of these amino acids in the Mn\(^{2+}\) induced degradation mechanism/ Golgi subcellular localization are not clear but one can think that they are part of a regulatory mechanism that delicately governs the Golgi ion homeostasis.

In conclusion, this paper highlights the importance of the two very conserved regions for the functionality of TMEM165 in Golgi glycosylation, its subcellular Golgi localization and Mn\(^{2+}\) sensitivity.
REFERENCES


ACKNOWLEDGEMENTS

This work was supported by grants from Agence Nationale de la Recherche (SOLV-CDG project to F.F.), and EURO-CDG-2 that has received a funding from the European Union’s Horizon 2020 research and innovation program under the ERA-NET Cofund action N° 643578. We are also indebted to Dr Dominique Legrand for the Research Federation FRABio (Univ. Lille, CNRS, FR 3688, FRABio, Biochimie Structurale et Fonctionnelle des Assemblages Biomoléculaires) for providing the scientific and technical environment conducive to achieving this work. We thank the BioImaging Center of Lille, especially Christian Slomianny and Elodie Richard, for the use of the Leica LSM700.

AUTHORS CONTRIBUTION


COMPETING INTERESTS

The author(s) declare no competing interests.
7. LEGEND TO FIGURES

Figure 1. Protein sequence alignment of TMEM165 and its orthologs PAM71 from Arabidopsis thaliana and Gdt1p from Saccharomyces cerevisiae

The sequences were found in Uniprot database (www.uniprot.org) and the protein sequence alignment was generated using Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo). Black boxes indicate the amino acid residues that are identical whereas gray boxes show the homologous amino acid residues. The black asterisks indicate the position of the generated mutated amino acids. The red asterisks indicate the mutated amino acids found in TMEM165-CDG patients. The bold characters correspond to the amino acid residues that are found conserved in the mammalian TMEM165 sequence (SwissProt Database) using the Cobalt-NCBI multiple alignment tool (NCBI). Conserved domains (motif 1 and 2) are highlighted in yellow. Black horizontal bars on the top of the sequences indicate the amino acids within the predictive transmembrane domains (TMHMM v2.0 server tool). The dotted line indicates the cytosolic central loop.

Figure 2. Impact of TMEM165 expression (wt and mutated forms) on LAMP2 glycosylation profile

TMEM165 KO HEK293T cells were transfected with empty-vector, wild-type or TMEM165 constructs. Total cells lysates were obtained, subjected to SDS-PAGE, Western blot was performed with the respective antibodies. A. LAMP2 and TMEM165 profiles obtained 24h after transfection. B. Ratio of fully glycosylated forms of LAMP2 (percentage of fully glycosylated forms versus total LAMP2). C. Immunofluorescence analysis of the expression and localization of TMEM165 in transfected cells with mutated forms of TMEM165 in conserved amino-acids (GM130 = Golgi marker). D. Illustration of red and green profiles with RGB Profiler (ImageJ Fiji®).
Figure 3. Sensitivity of TMEM165 mutants to manganese exposure

TMEM165 expression in cells transfected with mutated forms of TMEM165 in the conserved sequences and treated with or without 500µM Manganese (N≥3). Relative quantification of TMEM165 degradation at 4 and 8h manganese treatment is shown below each western blot. **A.** Sensitivity of TMEM165 in control cells and in TMEM165 KO HEK293T cells transfected with wt-TMEM165. **B.** Sensitivity of TMEM165 mutated in the E-x-G-D-K-[TF] motif. **C.** Sensitivity of TMEM165 mutated in the E-x-G-D-R-[SQ] motif.

Supplementary figure 1. Impact of TMEM165 expression (wt and mutated forms) on LAMP2 glycosylation profile.

TMEM165 KO HEK293T cells were transfected with empty-vector, wild-type or TMEM165 mutated forms. Total cells lysates were prepared, subjected to SDS-PAGE and western blot was performed with the respective antibodies. **A.** LAMP2 profiles obtained 24h after transfection.

Supplementary figure 2A. Subcellular localization of S253G-TMEM165

Localization of S253G-TMEM165 mutant and LAMP2 by immunofluorescence analysis. TMEM165 KO HEK293T cells transfected with S253G-TMEM165 mutant form were fixed and labeled with antibodies against LAMP2 and TMEM165 before confocal microscopy. Nuclei are labeled with DAPI staining. White arrows point co-localization of TMEM165 and LAMP2 in lysosomal structures.

Supplementary figure 2B. Subcellular localization of D251G-TMEM165

Localization of D251G-TMEM165 mutant and LAMP2 by immunofluorescence analysis. TMEM165 KO HEK293T cells transfected with D251G-TMEM165 mutant form were fixed
and labeled with antibodies against LAMP2 and TMEM165 before confocal microscopy. Nuclei are labeled with DAPI staining. White arrows point co-localization of TMEM165 and LAMP2 in lysosomal structures.

Supplementary figure 3. Effect of chloroquine (CQ) on manganese-induced degradation on lysine mutated forms of TMEM165

A. TMEM165 KO HEK293T cells transfected with K198R, K199R, K200R, K2008R, K199-200R mutants. Cells were incubated with 500µM of MnCl₂ for 4 hours, 8 hours and in combination of 8 hours of MnCl₂ and CQ 100µM. Total cell lysates were prepared, subjected to SDS-PAGE and western blot with TMEM165 antibodies. Black bars indicate percentage of TMEM165 without any treatment. Gray bars indicate percentage of TMEM165 left after 500µM of MnCl₂ for 4 hours, 8 hours or a combination of 8 hours of MnCl₂ and CQ 100µM with 1 hour of CQ pretreatment. B. Quantification of mutated TMEM165 forms expression with or without treatments. C. Subcellular localization of lysine mutated forms of TMEM165 by immunofluorescence and confocal microscopy experiments.
Fig. 1

<table>
<thead>
<tr>
<th>PAM71</th>
<th>MLNLNLSELSRIPFQNPRPFPKSDFSSTSSSPPSSRRCRVSAAYPIPIGFSV</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMEM165</td>
<td>--------------MAAAAP-------------GNGRASAPRLLLFLVPLLWAP</td>
</tr>
<tr>
<td>Gdtlp</td>
<td>----------------------------------</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PAM71</th>
<th>RNQYFRSCLTQLRRNESQQLGFCRQRNDAACYLEKAESEEHEHDRNLDVV</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMEM165</td>
<td>A----------AVRAGPDDELShRNKE---------------FPAP---AQQLQ</td>
</tr>
<tr>
<td>Gdtlp</td>
<td>----------------------------------</td>
</tr>
</tbody>
</table>

**

**

<table>
<thead>
<tr>
<th>PAM71</th>
<th>ESSIAHSRRERIQRVLAVSGVALLGTDPAFAASSIPNVTQSLVTSFG</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMEM165</td>
<td>PQFVAVQGFE----------PARVEKTTPAAPVHTNEDPATQ</td>
</tr>
<tr>
<td>Gdtlp</td>
<td>-MGNNMIKAS----------LIAALLPLTAAAATDAETSMEG</td>
</tr>
</tbody>
</table>

---

TM1

---

TM2

---

TM3

---

TM4

---

TM5

---

TM6

---
Fig. 2

A. HEK293 KO TMEM165

- |  |  |  |  |  |  |  |  |  |  |  |  | |

LAMP2

- 80
- 65
- 42

Fully glycosylated forms

Underglycosylated forms

β-actin

TMEM165

β-actin

B. % of fully/underglycosylated forms of LAMP2

- |  |  |  |  |  |  |  |  |  |  |  |  | |

Underglycosylated

Fully glycosylated
Fig. 2

C. WT-TMEM165  E108G-TMEM165  D111G-TMEM165  K112G-TMEM165  T113G-TMEM165  F114G-TMEM165

merge


D251G RG Profile

S253G RG Profile

Scale bar: 10µm
Fig. 3

A. HEK293T ctrl  HEK293T KO TMEM165

+WT-TMEM165

MnCl₂ 500µM (hrs) 0 4 8 0 4 8

B. HEK293T KO TMEM165

+WT-TMEM165

MnCl₂ 500µM (hrs) 0 4 8 0 4 8 0 4 8 0 4 8 0 4 8

C. HEK293T KO TMEM165

MnCl₂ 500µM (hrs) 0 4 8 0 4 8 0 4 8 0 4 8 0 4 8
Supp. Fig. 1
Supp. Fig. 2A

HEK KO TMEM165 + TMEM165-\textbf{S253G}

Scale bar: 10µm
Supp. Fig. 2B

HEK KO TMEM165 + TMEM165-D251G